PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Anoat Therapeutics receives cystic fibrosis funding boost

Vital financing will be used to develop novel therapies for conditions with high unmet medical needs.

Anoat Therapeutics – a company focusing on therapies for cystic fibrosis (CF) – has announced it has raised €2m in seed funding through its AdBio partners.

This critical investment – AFB FII – stems from a company recently established through the AdBio-Inserm Transfert partnership, established last year. The central aim of the collaboration is to finance, support and grow Europe’s most innovative life science start-ups.

Anoat will now use the funds to conduct additional in vivo and in vitro pharmacology assessments, while also defining a lead candidate.

Anoat’s ultimate aim is to bring a transformative therapy option to CF patients for whom existing therapies are not effective – specifically, patients not responsive to or eligible for CFTR (Cystic Fibrosis Transmembrane conductance Regulator) modulator therapies.

Alain Huriez, the managing partner of AdBio Partners, was in no doubt about the funding’s importance: “We are thrilled to have co-founded this first company with Inserm Transfert, bringing together state-of-the-art science developed by Inserm researchers and leading biotech development experts. AdBio Partners’ mission is to support founding scientists in the development of new therapeutic approaches.”

Pascale Augé, Chairman of the executive management board at Inserm Transfert, reflected: “The launch of this first company resulting from the alliance built with AdBio Partners just a year earlier is a great achievement.

“It shows that our respective fields of expertise complement each other and that a close relationship between Inserm Transfert and AdBio Partners facilitates the emergence and early financing of innovative life sciences companies.”

Cystic fibrosis is a progressive genetic disease that affects the pancreas, lungs and several other organs. It is estimated that 105,000 people have been diagnosed with the condition across 94 countries.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026